“…In addition to these encouraging safety findings, all patients who received 13 weeks of treatment with KZR-616 showed at least some improvement across diseases measures, such as the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), despite enrolling in the study with active disease. Reductions in circulating class switched B-cells and plasma cells were observed and in all eight patients with an abnormal level of anti-dsDNA antibodies at baseline, reductions at either Week 13 (end of treatment) and/or Week 25 (end of study) were observed ( Figure 4 ) [ 56 , 57 ]. Finally, in two of two patients with active, proliferative LN enrolled in the Ph 1b portion of the study, improvements in proteinuria were seen within 17 weeks from treatment initiation.…”